Analyst consensus rating
Actuate Therapeutics Analyst Rating: none
Direct answer
Actuate Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.68.
Forecast evidence checked November 4, 2026.
Get free Actuate Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.35
- Average price target
- $11.68
- High price target
- $15.05
- Low price target
- $8.00
- Low target gap
- +2,185.7%
- Target upside
- +3,238.1%
- High target gap
- +4,200%
- Target range width
- 2,014.3%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- November 4, 2026
- Valid through
- November 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Actuate Therapeutics?
Actuate Therapeutics has a verified none consensus. The same dataset has an average price target of $11.68.
How far are Actuate Therapeutics's low and high targets from the recorded price?
The low target implies +2,185.7%, while the high target implies +4,200%.
How many analysts are included in Actuate Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Actuate Therapeutics's target upside or downside calculated?
The average target of $11.68 is divided by the recorded price of $0.35, then one is subtracted to produce +3,238.1%. This does not guarantee a future return.
When was Actuate Therapeutics's analyst forecast verified?
The data was verified on 2026-11-04. The dataset is valid through 2026-11-11.